Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a Healthcare company (Biotechnology) with a market capitalization of $1.3B. The Maz Rating grades it against the other companies in its sector.
Ocular Therapeutix, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $6.02, Ocular Therapeutix, Inc. trades at 26.4x sales and 3.1x book value. Over the last twelve months it generated about $50M of revenue and a net loss of $319M. It runs a gross margin of 87.3%, an operating margin of -680.9% and a net margin of -648.6%. It shows return on equity of -59.5%, return on invested capital of -62.9% and a free cash flow yield of -20.2%. On the balance sheet: a debt-to-equity ratio of 0.18 and a current ratio of 9.12. Over the past 52 weeks the share price ranged from $5.80 to $16.44, with a beta of 0.99.
Ocular Therapeutix, Inc. does not currently pay a dividend.
19 Wall Street analyst ratings cover the stock: 1 Strong Buy, 16 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.